PharmaBlock Sciences (Nanjing) Balance Sheet Health
Financial Health criteria checks 4/6
PharmaBlock Sciences (Nanjing) has a total shareholder equity of CN¥2.9B and total debt of CN¥1.6B, which brings its debt-to-equity ratio to 54.9%. Its total assets and total liabilities are CN¥5.0B and CN¥2.1B respectively. PharmaBlock Sciences (Nanjing)'s EBIT is CN¥265.0M making its interest coverage ratio 5.5. It has cash and short-term investments of CN¥660.6M.
Key information
54.9%
Debt to equity ratio
CN¥1.58b
Debt
Interest coverage ratio | 5.5x |
Cash | CN¥660.59m |
Equity | CN¥2.88b |
Total liabilities | CN¥2.09b |
Total assets | CN¥4.96b |
Recent financial health updates
Recent updates
We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
Jul 31PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31
Jun 12PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Apr 21PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump
Mar 07Financial Position Analysis
Short Term Liabilities: 300725's short term assets (CN¥2.7B) exceed its short term liabilities (CN¥868.8M).
Long Term Liabilities: 300725's short term assets (CN¥2.7B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 300725's net debt to equity ratio (31.9%) is considered satisfactory.
Reducing Debt: 300725's debt to equity ratio has increased from 8.7% to 54.9% over the past 5 years.
Debt Coverage: 300725's debt is not well covered by operating cash flow (14.4%).
Interest Coverage: 300725's interest payments on its debt are well covered by EBIT (5.5x coverage).